Royalty Pharma (STU:RPD) Ending Cash Position : €887 Mil (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Royalty Pharma Ending Cash Position?

Royalty Pharma's Ending Cash Position for the quarter that ended in Dec. 2024 was €887 Mil.

Royalty Pharma's quarterly Ending Cash Position declined from Jun. 2024 (€1,639 Mil) to Sep. 2024 (€856 Mil) but then increased from Sep. 2024 (€856 Mil) to Dec. 2024 (€887 Mil).

Royalty Pharma's annual Ending Cash Position declined from Dec. 2022 (€1,615 Mil) to Dec. 2023 (€437 Mil) but then increased from Dec. 2023 (€437 Mil) to Dec. 2024 (€887 Mil).

Royalty Pharma Ending Cash Position Historical Data

The historical data trend for Royalty Pharma's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Royalty Pharma Ending Cash Position Chart

Royalty Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Ending Cash Position

Get a 7-Day Free Trial

829.14

1,363.83

1,614.95

437.42

887.22

Royalty Pharma Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Ending Cash Position	Get a 7-Day Free Trial															437.42	775.56	1,639.35	856.00	887.22

Royalty Pharma Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Royalty Pharma's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	455.545	+	431.675
	=	887

Royalty Pharma's Ending Cash Position for the quarter that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	907.301	+	-20.081
	=	887

Royalty Pharma Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Royalty Pharma's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Royalty Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Royalty Pharma PLC (STU:RPD) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

RPRX:USA RPRX:Mexico

Address

110 East 59th Street, New York, NY, USA, 10022

Website

https://www.royaltypharma.com

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.